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effective when a willingness to pay (WTP) was $33,000/QALY
or less and TIO + SFC was more cost-effective when a WTP
exceeded that threshold. The cost-effectiveness was also sensitive
to changes in several variables including the mortality rates and
utilities associated with TIO + SAL and TIO + SFC, as well as
the hospitalization rate associated with TIO + SAL. CONCLU-
SION: When monotherapy with TIO is not effective to control
moderate to severe COPD, adding SFC rather than SAL appears
to be a more reasonable approach from a cost-effectiveness
standpoint in the US health care system. However, the results
were sensitive to changes in several key variables.
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OBJECTIVE: Management of pediatric asthma is known to be
very costly. However, little is known about the costs to the
parent. We aimed to objectively assess employee and dependent
costs for employees with children with asthma (EWCWA)
compared with employees with children without asthma
(EWCWOA). METHODS: A retrospective analysis was con-
ducted using multiple US-based employers’ data from 2001 to
2007. Data included medical claims, pharmacy claims, payroll,
work absence, and demographics. Asthma diagnosis (ICD-9
codes 493.xx) or pharmacy claims for an asthma controller
medication were used to identify employees with asthmatic
dependents aged <12 years for the EWCWA cohort. Employees
in the EWCWOA cohort were identiﬁed based on dependent age
and lack of an asthma diagnosis (ICD-9 code) or pharmacy claim
for a controller medication. The index date in the EWCWA
cohort was deﬁned as the date of ﬁrst asthma diagnosis during
2001 or later; the ﬁrst pediatric medical or pharmacy claim date
was used in the EWCWOA cohort. All costs were adjusted to
2007 dollars and incremental costs (EWCWA—EWCWOA)
were calculated using two-part regression models and presented
for health care and prescriptions. Regression models controlled
for demographics, job information, Charlson Co-morbidity
Index, and geographic region. RESULTS: Data were available for
the EWCWA (dependent age <4 yr: n = 4577; 4–7 yr: n = 4343;
8–11 yr: n = 3954; total <12 yr: n = 11,794) and EWCWOA
(dependent age <4 yr: n = 32,558; 4–7 yr: n = 28,017; 8–11 yr:
n = 27,863; total <12 yr: n = 64,812) cohorts. The incremental
annual costs (EWCWA—EWCWOA) for employees and depen-
dents (health care/prescriptions), respectively, were: dependent
age <4 years: -$56/$73† and $663†/$568†; 4–7 years: $199*/
$109† and $904†/$555†; 8–11 years: $364*/$116† and $1081†/
$586†; <12 years: $154†/$95 and $862/$534 (*P < 0.05,
†P < 0.01). CONCLUSION: Pediatric asthma results in signiﬁ-
cant additional costs for both employees and dependents.
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OBJECTIVE: The prevalence of chronic asthma has tripled
during last two decades in Finland, but overall costs of disease
management have not increased and patient level costs have
decreased signiﬁcantly. We analyzed with comprehensive time
series all expenditures as well as the effectiveness of interventions
such as the national action program (1994–2004) and develop-
ment of pharmacotherapy. METHODS: Finnish registry based
data from 1987 to 2005 was combined to evaluate all costs of
asthma. These included comprehensive health care costs, sick-
leave compensations, disability pensions, and loss of produc-
tivity; all converted to 2004 euros. Several scenarios were
constructed to identify the important changes in care processes
and cost drivers during this period. RESULTS: The number of
patients with valid special reimbursement for asthma medication
increased signiﬁcantly (83,000 to 216,000) during the observa-
tion period yet the overall expenditure of care remained at the
level of 1987, at €240 million. Cost of medications doubled
during study period, but savings were achieved as other
expenditures, mainly hospitalizations, and loss of productivity
decreased by 50 to 75%. Treatment effectiveness increased as
asthma related deaths, disability pensions, sick-leave payments
and institutional care decreased signiﬁcantly (50 to 70%). The
cost-saving scenarios showed that a signiﬁcant part (40%) of
positive effects was attained by launch of new asthma drugs and
asthma pipes from 1989 to 1994. The initiation of the national
care programme with its focus on anti-inﬂammatory treatment
from disease onset, improved diagnostics and more active self
care further increased this positive trend. CONCLUSION: Com-
prehensive assessment of large patient cohorts and long term
economical outcomes is a useful method for evaluation of out-
comes in chronic diseases. Identiﬁcation of different cost drivers
is needed as the cost of new interventions is increasing and their
beneﬁts should ideally be assessed in relation to their broader
societal inﬂuence.
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OBJECTIVE: The prevalence and costs of allergic rhinitis (AR)
in the United States are estimated to be very high. Recently,
research has reported that not all AR symptoms are of equal
importance to patients. In particular, evidence is mounting that
nasal congestion is the most bothersome symptom of AR and
thus may account for most of the burden of illness. However,
unlike AR which has an ICD-9-CM code thus facilitating esti-
mates of burden of illness, the cost of nasal congestion must be
obtained indirectly. The purpose of the present analysis is to
estimate the national costs of AR that are attributable to nasal
congestion. METHODS: Data come from a recent national study
of the effect of AR symptoms on patients’ lives (e.g., sleep,
daytime somnolence, mood, and work and school productivity).
These relative effects of nasal congestion were then applied to
U.S. cost estimates derived from the literature and a national
employer claims database to estimate some of the economic
burden of AR that could be attributed to nasal congestion.
RESULTS: Results suggest that almost three-fourths of the cost
associated with burden of illness related to AR is attributable to
nasal congestion. Thus, approximately $3.4 billion of the $4.8
billion in direct costs for AR and approximately $3.1 billion of
the $4.3 billion in indirect costs for AR can be attributed to nasal
congestion. CONCLUSION: The direct and indirect costs attrib-
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